Open AccessGlioblastoma in natalizumab‐treated multiple sclerosis patients
Author(s) -
Sierra Morales Fabian,
Wright Robert B.,
Novo Jorge E.,
Arvanitis Leonidas D.,
Stefoski Dusan,
Koralnik Igor J.
Publication year - 2017
Publication title -
annals of clinical and translational neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.824
H-Index - 42
ISSN - 2328-9503
DOI - 10.1002/acn3.428
Subject(s) - medicine , natalizumab , isocitrate dehydrogenase , multiple sclerosis , idh1 , glioblastoma , oncology , astrocytoma , immunology , cancer research , mutant , biochemistry , chemistry , gene , enzyme
We present two natalizumab‐treated multiple sclerosis patients who developed glioblastoma multiforme ( GBM ) with variable outcomes. One patient had an isocitrate dehydrogenase ( IDH )‐wildtype GBM with aggressive behavior, who declined treatment and died 13 weeks after symptoms onset. The other patient underwent resection of an IDH ‐mutant secondary GBM that arose from a previously diagnosed grade II astrocytoma. He is still alive 5 years after the diagnosis of GBM . JC virus was not detected in either case. Whether natalizumab played a role in the development of GBM in those patients deserves further investigation.